Russia Poised to Register COVID-19 Vaccine Developed by Chumakov Center


Russia is poised to register its third vaccine against COVID-19, Anna Popova, the head of public health watchdog Rospotrebnadzor, said on Friday, noting that the clinical trials of a vaccine developed by the Chumakov research center of the Russian Academy of Sciences were positive, Sputnik reports.

“I know that the Chumakov Center should receive a registration certificate in the coming days, but the results from the center are already very positive and speak for themselves,” Popova said the Gaidar Forum.

The Russian government has so far registered Sputnik V, a vaccine against COVID-19 developed by the Gamaleya institute, and EpiVacCorona, developed by Russia’s State Research Center of Virology and Biotechnology Vector.

Chumakov research center of Russian Academy of Sciences previously stated that it would begin Stage III clinical trial of its coronavirus vaccine in February.

Earlier, head of Rospotrebnadzor said that at least 10 more vaccines are being developed in Russia.